Advances in targeted therapies for colorectal cancer
John Strickler, MD, Duke University, Durham, NC, gives an overview of how strategies targeting BRAF have included clinical testing for V600E mutations in recent years. KRAS G12C inhibitors are showing striking activity for KRAS G12C-mutant colorectal cancer. Additionally, anti-HER2 treatment has shown interesting results in patients with HER2-positive colorectal cancer. In the USA, there is an FDA anti-HER2 approved regimen. In the future, in order to widen the scope of understanding surrounding GI cancers, other KRAS variants need to be studies, such as KRAS G12D. This interview took place at the ESMO World Congress on Gastrointestinal Cancer (WCGIC) 2023 in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
-
Category
No comments found